Document Detail

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer.
MedLine Citation:
PMID:  12010834     Owner:  NLM     Status:  MEDLINE    
The feasibility and toxicity of allogeneic stem cell transplantation after nonmyeloablative conditioning including thiotepa, fludarabine, and cyclophosphamide have been investigated in 6 patients with breast cancer and 7 patients with renal cell cancer. The program included the use of escalating doses of donor lymphocyte infusions (DLI) and/or interferon alpha (IFNalpha) for patients showing no tumor response and no graft-versus-host disease (GVHD). Patients were at high risk of transplant-related mortality (TRM) because of age, advanced stage, and previous treatments. We observed a partial remission in 4 renal cancer and in 2 breast cancer patients (one at the molecular level in the bone marrow), occurring after cyclosporine withdrawal or after DLI and/or IFNalpha. All the responses were accompanied by the occurrence of acute GVHD. We conclude that reduced-intensity allogeneic stem cell transplantation is a feasible procedure in renal and breast cancer, and that the exploitation of graft-versus-tumor effect after DLI is a promising finding.
Marco Bregni; Anna Dodero; Jacopo Peccatori; Alessandra Pescarollo; Massimo Bernardi; Isabella Sassi; Claudia Voena; Alberto Zaniboni; Claudio Bordignon; Paolo Corradini
Related Documents :
3525864 - Immunological assessment of renal cancer patients as evaluated by the lymphocyte adhere...
21245094 - Smad4 inactivation promotes malignancy and drug resistance of colon cancer.
17761094 - Laparoscopic adrenalectomy for large adrenal metastasis from contralateral renal cell c...
18537654 - Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.
15655594 - Prognostic significance of mucinous component in colorectal carcinoma.
11731224 - Butylamino-demethoxy-hypocrellins and photodynamic therapy decreases human cancer in vi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood     Volume:  99     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-05-15     Completed Date:  2002-07-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4234-6     Citation Subset:  AIM; IM    
Bone Marrow Transplant Unit and Gene Therapy Program and the Division of Pathology, Istituto H San Raffaele, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / pathology,  therapy*
Carcinoma, Renal Cell / therapy*
Hematopoietic Stem Cell Transplantation*
Kidney Neoplasms / pathology,  therapy*
Lymphocyte Transfusion*
Middle Aged
Neoplasm Metastasis
Nuclear Family
Platelet Transfusion*
Tissue Donors
Transplantation, Homologous / immunology*,  methods
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular basis of NB1 (HNA-2a, CD177) deficiency.
Next Document:  Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenoc...